The antiplatelet drugs commonly used in clinical have certain antithrombotic effects,but all carry an inherent risk of bleeding,which is associated with serious cardiovascular adverse events or even death.Recent preclinical studies have found that in?hibiting phosphatidylinositol 3?kinase?β(PI3Kβ),protein disulfide?isomerase,GPⅡb/Ⅲa outside?in signalling,protease?activated re?ceptors and platelet GPVI?mediated adhesion pathways can inhibit thrombosis while maintaining haemostasis at the same time, which may lead to more effective and safer treatment method.